JB Chemicals Financials
| JBCHEPHARM | 1,841 25.75 1.42% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 7.9 B | 7.5 B |
|
|
JBCHEPHARM | Select Account or Indicator |
JB Chemicals Stock Summary
JB Chemicals competes with Kingfa Science, Rico Auto, GACM Technologies, COSMO FIRST, and Delta Manufacturing. JB Chemicals is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE572A01028 |
| Business Address | Cnergy IT Park, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.jbpharma.com |
| Phone | 91 22 2439 5200 |
You should never invest in JB Chemicals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of JBCHEPHARM Stock, because this is throwing your money away. Analyzing the key information contained in JB Chemicals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
JB Chemicals Key Financial Ratios
JB Chemicals' financial ratios allow both analysts and investors to convert raw data from JB Chemicals' financial statements into concise, actionable information that can be used to evaluate the performance of JB Chemicals over time and compare it to other companies across industries.| Revenue | 34.48 B | ||||
| Gross Profit | 19.81 B | ||||
| EBITDA | 9.33 B | ||||
| Net Income | 5.53 B | ||||
| Cash And Equivalents | 269.12 M |
JB Chemicals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 18.1B | 22.4B | 26.1B | 35.5B | 39.9B | 41.9B | |
| Other Current Liab | 911.3M | 1.1B | 1.1B | 236.5M | 1.4B | 1.0B | |
| Net Debt | 92.1M | 163.0M | (19.9M) | 5.0B | 2.9B | 3.0B | |
| Retained Earnings | 12.3B | 15.8B | 18.4B | 22.8B | 25.1B | 26.4B | |
| Accounts Payable | 1.7B | 1.9B | 2.2B | 2.4B | 3.6B | 3.7B | |
| Cash | 290.1M | 286.9M | 565.4M | 769.3M | 882.2M | 531.0M | |
| Net Receivables | 3.6B | 3.9B | 6.2B | 5.8B | 7.0B | 3.8B | |
| Inventory | 2.7B | 3.5B | 4.1B | 4.3B | 5.0B | 5.3B | |
| Other Current Assets | 4.4B | 5.1B | 8.1B | 2.3B | 1.9B | 2.6B | |
| Total Liab | 3.8B | 4.2B | 4.7B | 10.7B | 10.7B | 11.2B | |
| Total Current Assets | 10.7B | 15.5B | 12.7B | 15.3B | 18.5B | 10.3B | |
| Common Stock | 167.1M | 160.5M | 154.6M | 154.8M | 155.2M | 131.5M | |
| Intangible Assets | 300.9M | 321.1M | 6.7B | 13.2B | 13.9B | 14.6B | |
| Short Term Debt | 344.5M | 398.5M | 339.4M | 1.7B | 3.4B | 3.6B | |
| Other Liab | 648.4M | 680.7M | 742.7M | 644.6M | 741.2M | 536.5M | |
| Net Tangible Assets | 14.0B | 13.5B | 17.2B | 14.1B | 16.2B | 14.2B | |
| Other Assets | 105.3M | 133.8M | 241.6M | 123.8M | 142.4M | 130.7M | |
| Short Long Term Debt | 320.4M | 326.4M | 263.2M | 1.7B | 3.3B | 3.5B | |
| Long Term Debt Total | 12.3M | 51.4M | 206.2M | 4.0B | 4.6B | 4.8B | |
| Net Invested Capital | 14.7B | 18.4B | 21.6B | 30.3B | 32.8B | 23.2B | |
| Cash And Equivalents | 290.1M | 33.9M | 18.2M | 269.1M | 309.5M | 325.0M |
JB Chemicals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 29.2M | 69.4M | 47.9M | 360.5M | 443.3M | 465.5M | |
| Total Revenue | 17.4B | 20.1B | 24.2B | 31.5B | 34.5B | 36.2B | |
| Gross Profit | 10.9B | 12.9B | 15.6B | 27.7B | 13.3B | 9.7B | |
| Operating Income | 3.2B | 4.9B | 4.7B | 5.9B | 7.5B | 7.9B | |
| Ebit | 3.5B | 6.0B | 5.1B | 5.9B | 8.0B | 8.3B | |
| Ebitda | 4.2B | 6.7B | 5.8B | 7.0B | 9.3B | 9.8B | |
| Cost Of Revenue | 6.5B | 7.2B | 8.6B | 3.8B | 21.2B | 22.3B | |
| Income Before Tax | 3.5B | 6.0B | 5.0B | 27.7B | 7.5B | 4.4B | |
| Net Income | 2.7B | 4.5B | 3.9B | 4.1B | 5.5B | 5.8B | |
| Income Tax Expense | 765.0M | 1.5B | 1.2B | 893.1M | 2.0B | 2.1B | |
| Research Development | 193.9M | 235.3M | 291.1M | 319.3M | 356.7M | 270.5M | |
| Minority Interest | 28.0M | 25.0M | 37.1M | (6.8M) | (1.7M) | 0.0 | |
| Tax Provision | 782.0M | 1.5B | 1.2B | 893.1M | 2.0B | 1.1B | |
| Interest Income | 333.2M | 72.4M | 51.2M | 360.5M | 44.3M | 42.1M | |
| Net Interest Income | (4.1M) | (72.4M) | (51.2M) | (360.5M) | (443.3M) | (421.1M) |
JB Chemicals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of JB Chemicals Pharmac. It measures of how well JBCHEPHARM is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money JB Chemicals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money JBCHEPHARM had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what JB Chemicals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (309.1M) | (700.9M) | (625.1M) | (205.2M) | (720.3M) | (684.3M) | |
| Change In Cash | (63.9M) | (32.8M) | 340.7M | 203.9M | 112.8M | 118.4M | |
| Free Cash Flow | 2.0B | 2.7B | (5.4B) | (1.4B) | 5.4B | 5.7B | |
| Depreciation | 663.2M | 686.7M | 726.6M | 1.1B | 1.4B | 1.5B | |
| Other Non Cash Items | (1.5B) | (2.6B) | 10.3M | 311.9M | 2.1B | 2.2B | |
| Dividends Paid | 1.4B | 732.4M | 1.3B | 1.3B | 1.6B | 825.3M | |
| Capital Expenditures | 729.7M | 477.7M | 7.1B | 7.6B | 2.6B | 1.6B | |
| Net Income | 3.5B | 6.0B | 5.0B | 5.6B | 5.5B | 3.0B | |
| End Period Cash Flow | 257.5M | 224.7M | 565.4M | 769.3M | 882.2M | 926.3M | |
| Investments | 912.6M | (2.2B) | 7.0B | (9.6B) | (4.0B) | (3.8B) | |
| Net Borrowings | (500K) | (23.6M) | (78.3M) | (83.7M) | (75.3M) | (71.5M) | |
| Change To Netincome | (33.1M) | (723.2M) | (1.1B) | 146.4M | 131.7M | 138.3M |
JBCHEPHARM Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining JB Chemicals's current stock value. Our valuation model uses many indicators to compare JB Chemicals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across JB Chemicals competition to find correlations between indicators driving JB Chemicals's intrinsic value. More Info.JB Chemicals Pharmaceuticals is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for JB Chemicals Pharmaceuticals is roughly 1.59 . Comparative valuation analysis is a catch-all model that can be used if you cannot value JB Chemicals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for JB Chemicals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.JB Chemicals Pharmac Systematic Risk
JB Chemicals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. JB Chemicals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on JB Chemicals Pharmac correlated with the market. If Beta is less than 0 JB Chemicals generally moves in the opposite direction as compared to the market. If JB Chemicals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one JB Chemicals Pharmac is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of JB Chemicals is generally in the same direction as the market. If Beta > 1 JB Chemicals moves generally in the same direction as, but more than the movement of the benchmark.
JB Chemicals Pharmaceuticals Total Assets Over Time
JB Chemicals Thematic Clasifications
JB Chemicals Pharmaceuticals is part of several thematic ideas from Synthetics to Chemicals Makers. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasJB Chemicals December 13, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of JB Chemicals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of JB Chemicals Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of JB Chemicals Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing JBCHEPHARM Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build JB Chemicals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 8.89 | |||
| Value At Risk | (3.50) | |||
| Potential Upside | 2.89 |
Complementary Tools for JBCHEPHARM Stock analysis
When running JB Chemicals' price analysis, check to measure JB Chemicals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy JB Chemicals is operating at the current time. Most of JB Chemicals' value examination focuses on studying past and present price action to predict the probability of JB Chemicals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move JB Chemicals' price. Additionally, you may evaluate how the addition of JB Chemicals to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |